News Search Results
Nov 13, 2025, 22:30 ET Laboratory Centrifuges Market worth $1.86 billion by 2030 with 2.8% CAGR | MarketsandMarkets™
regional market, mainly due to the presence of emerging economies like China and India and the increasing R&D investments by pharmaceutical and biotechnology companies in this region. Download PDF Brochure:
More news about: MarketsandMarkets
Nov 13, 2025, 21:10 ET KHB presenta el FOCUS PEGASUS MF200 mejorado: redefiniendo la eficiencia en el diagnóstico veterinario
XI'AN, China, 14 de noviembre de 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd., filial de KHB Group e innovadora en soluciones de diagnóstico veterinario en el punto de atención (POCT), presenta el analizador veterinario
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 13, 2025, 20:27 ET KHB、改良型FOCUS PEGASUS MF200を披露 -- 獣医診断の効率性を再定義
中国西安、2025年11月14日 /PRNewswire/ -- KHBグループの子会社であり、獣医向けポイントオブケア（POCT）ソリューションのイノベーターであるGuangzhou Focus Biotechnology Co., Ltd.は、改良型FOCUS PEGASUS MF200 自動多機能獣医用アナライザーを発表した。次世代システムとして、獣医診断における効率性、信頼性、アクセス性を再定義する。
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 13, 2025, 20:27 ET KHB, 업그레이드된 'FOCUS PEGASUS MF200' 공개 -- 수의 진단 효율성 재정의
시안, 중국 2025년 11월 14일 /PRNewswire/ -- KHB 그룹의 자회사이자 수의 현장 진단(POCT) 솔루션 혁신 기업인 광저우 포커스 바이오테크놀로지(Guangzhou Focus Biotechnology Co., Ltd.)가 자동 다기능 수의학 분석기 'FOCUS PEGASUS MF200' 업그레이드 버전을 선보였다. MF200은 수의 진단 분야에서 효율성, 신뢰성, 접근성을 새롭게 정의하는 차세대 시스템이다.
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 13, 2025, 16:05 ET Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design
More news about: Kodiak Sciences Inc.
Nov 13, 2025, 15:38 ET General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform
SAN FRANCISCO, Nov. 12, 2025 /PRNewswire/ -- General Proximity, a biotechnology company discovering and developing the next generation of induced proximity medicines, today announced a strategic multi-target collaboration with
More news about: General Proximity
Nov 13, 2025, 11:07 ET Immune Reactions Found Behind Human Rejection of Transplanted Pig Kidneys
Society; LiveOnNY; the National Kidney Foundation; Sanofi-Aventis U.S.; and Lung Biotechnology, a subsidiary of United Therapeutics, and PBC BioMed. He has also previously served on the advisory boards for the biotechnology companies eGenesis and Recombinetics. The terms and conditions of all of these
More news about: NYU Grossman School of Medicine and NYU Langone Health
Nov 13, 2025, 10:17 ET Medical Radiation Shielding Market is expected to generate a revenue of USD 3.27 Billion by 2035, Globally, at 6.7% CAGR | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Nov 13, 2025, 10:04 ET NNT 2025 Celebrates 30 Years of Nanoimprint -- One of the Most Transformative Technologies of the 21st Century
by Nanoimprint include consumer electronics (augmented-reality (AR) and virtual-reality (VR) goggles, smart glasses, displays, and smartphones); biotechnology and life sciences (gene sequencing, biosensing, biomedical, and pharmaceutical applications); photonics and optical communications (LEDs, lasers,
More news about: NNT Conference
Nov 13, 2025, 10:01 ET ACMA's Next-Generation Artificial Intelligence Board Certification for Medical Science Liaisons
leader in life sciences accreditation, certification, and professional training, setting the gold standard for excellence across the pharmaceutical, biotechnology, and healthcare sectors. Through its flagship Board Certified Medical Affairs Specialist (BCMAS®) program, ACMA empowers medical affairs and field
More news about: Accreditation Council for Medical Affairs (ACMA)
Nov 13, 2025, 09:27 ET BiomEdit Announces USDA Finding of No Significant Impact Letter for Non-Antibiotic Poultry Biologic, Clearing Path to Field Safety Trials
GREENFIELD, Ind., Nov. 13, 2025 /PRNewswire/ -- BiomEdit, Inc., a pioneering animal health biotechnology company, today announced it has received a Finding of No Significant Impact (FONSI) letter from the U.S. Department of Agriculture's (USDA) Animal
More news about: BiomEdit
Nov 13, 2025, 09:00 ET Sentinel BioTherapeutics Appoints Dr. Zelanna Goldberg to Board of Directors and as Chair of Clinical Advisory Board
Nov. 13, 2025 /PRNewswire/ -- RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building biotechnology companies, and portfolio company Sentinel BioTherapeutics, a clinical-stage company developing encapsulated protein producers (ePPs) that enable
More news about: Sentinel BioTherapeutics
Nov 13, 2025, 08:33 ET CNS Summit 2025 Honors Robert Langer with Leadership Award for Transformative Impact in Life Sciences Innovation
contributions to biotechnology, drug development and translational research. Dr. Langer is one of the most influential figures in biotechnology. His pioneering work has led to many breakthroughs in treatments for patients, and the creation of more than 40 biotechnology companies. Recipient
More news about: CNS Summit
Nov 13, 2025, 08:30 ET Why Transmission Electron Microscopy Is Key to Cell Line Characterization, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 13, 2025, 08:30 ET Riding the data wave: How pharma can navigate disruptions in open claims, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 13, 2025, 08:05 ET Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
(Nasdaq: THAR) ("Tharimmune" or the "Company"), a digital asset treasury company with a clinical-stage biotechnology function, today announced an update from the biotechnology side of the business. Its lead clinical asset, TH104 (nalmefene buccal film), received positive feedback from the
More news about: Tharimmune, Inc.
Nov 13, 2025, 08:00 ET LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner
SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Material Transfer Agreement (MTA) with a leading
More news about: LISCure BioSciences
Nov 13, 2025, 08:00 ET RegCell Announces Two Peer-Reviewed Publications Supporting its Robust Scientific Foundation on Antigen-Specific Tolerance to Treat Autoimmune Diseases
EMERYVILLE, Calif., Nov. 13, 2025 /PRNewswire/ -- RegCell, Inc. a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the
More news about: RegCell, Inc.
Nov 13, 2025, 07:42 ET Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer
Domain Therapeutics, said: "I am delighted to welcome Jean-Marie to the team. A distinguished industry leader with extensive expertise in the biotechnology and pharmaceutical sector, and a proven track record of leading clinical teams and optimizing clinical strategies, he is ideally positioned to help
More news about: Domain Therapeutics
Nov 13, 2025, 07:30 ET Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Nov 13, 2025, 07:00 ET Tract Bio Announces Opening of New Laboratory at The Pearl Innovation District
CHARLOTTE, N.C., Nov. 13, 2025 /PRNewswire/ -- Tract Bio ("Tract"), a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced the official opening of its new laboratory
More news about: Tract Bio
Nov 13, 2025, 06:59 ET Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
WALTHAM, Mass., Nov. 13, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial
More news about: Q32 Bio
Nov 13, 2025, 06:30 ET Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the
More news about: Immunic, Inc.
Nov 13, 2025, 05:00 ET Yatsen Group Unveils Beauty Innovation Insight, Defining the Next Era of World-Class Beauty Science
3 proprietary R&D centers 4 frontier research domains: Biotechnology, Scientific Skincare, Emotional Skincare, and Skin Data Science 6 joint laboratories
More news about: Yatsen Holding Limited
Nov 13, 2025, 03:08 ET KHB Showcases the Enhanced FOCUS PEGASUS MF200 -- Redefining Efficiency in Veterinary Diagnostics
XI'AN, China, Nov. 13, 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd., a subsidiary of KHB Group and an innovator in veterinary point-of-care testing (POCT) solutions, presents the enhanced FOCUS PEGASUS
More news about: Shanghai Kehua Bio-engineering Co., Ltd.